Search results
Results from the WOW.Com Content Network
The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk .
The United Kingdom Accreditation Service (UKAS) is the sole national accreditation body recognised by the British government [1] to assess the competence of organisations that provide certification, testing, inspection and calibration services. It evaluates these conformity assessment bodies and then accredits them where they are found to meet ...
The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS).
[15] [16] Because the drug was the first GLP-1 agonist that could be taken once a day, sales projections in 2013 were €500M per year by 2018. [16] Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. [17]
Entecavir is in the nucleoside reverse transcriptase inhibitors (NRTIs) family of medications. [6] [7] It prevents the hepatitis B virus from multiplying by blocking reverse transcriptase. [6] Entecavir was approved for medical use in 2005. [6] It is on the World Health Organization's List of Essential Medicines. [8] It is available as a ...
A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). [1] The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming ...
Tofacitinib was initially not approved by European regulatory agencies because of concerns over efficacy and safety, [23] although by 2018, the European Commission had approved it. [24] Animal studies with tofacitinib conducted prior to human trials showed some carcinogenesis , mutagenesis , and impairment of fertility .
[9] [8] Use is not recommended during pregnancy or breastfeeding. [9] It inhibits xanthine oxidase, thus reducing production of uric acid in the body. [7] Febuxostat was approved for medical use in the European Union in 2008, [5] and in the United States in 2009. [7] A generic version was approved in 2019. [10] [11]